184 related articles for article (PubMed ID: 19554571)
21. Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.
Suzuki T; Fujii A; Ohya J; Amano Y; Kitano Y; Abe D; Nakamura H
Cancer Sci; 2007 Dec; 98(12):1977-84. PubMed ID: 17888033
[TBL] [Abstract][Full Text] [Related]
22. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
Strecker TE; Shen Q; Zhang Y; Hill JL; Li Y; Wang C; Kim HT; Gilmer TM; Sexton KR; Hilsenbeck SG; Osborne CK; Brown PH
J Natl Cancer Inst; 2009 Jan; 101(2):107-13. PubMed ID: 19141783
[TBL] [Abstract][Full Text] [Related]
23. Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
Reynolds CP; Kang MH; Carol H; Lock R; Gorlick R; Kolb EA; Kurmasheva RT; Keir ST; Maris JM; Billups CA; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2013 May; 60(5):791-8. PubMed ID: 23002019
[TBL] [Abstract][Full Text] [Related]
24. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.
Rusnak DW; Alligood KJ; Mullin RJ; Spehar GM; Arenas-Elliott C; Martin AM; Degenhardt Y; Rudolph SK; Haws TF; Hudson-Curtis BL; Gilmer TM
Cell Prolif; 2007 Aug; 40(4):580-94. PubMed ID: 17635524
[TBL] [Abstract][Full Text] [Related]
25. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
Zhang D; Pal A; Bornmann WG; Yamasaki F; Esteva FJ; Hortobagyi GN; Bartholomeusz C; Ueno NT
Mol Cancer Ther; 2008 Jul; 7(7):1846-50. PubMed ID: 18644997
[TBL] [Abstract][Full Text] [Related]
26. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
[TBL] [Abstract][Full Text] [Related]
27. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.
Gorlick R; Kolb EA; Houghton PJ; Morton CL; Neale G; Keir ST; Carol H; Lock R; Phelps D; Kang MH; Reynolds CP; Maris JM; Billups C; Smith MA
Pediatr Blood Cancer; 2012 Dec; 59(7):1266-74. PubMed ID: 22315240
[TBL] [Abstract][Full Text] [Related]
28. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.
Singh A; Lun X; Jayanthan A; Obaid H; Ruan Y; Strother D; Chi SN; Smith A; Forsyth P; Narendran A
Mol Oncol; 2013 Jun; 7(3):497-512. PubMed ID: 23375777
[TBL] [Abstract][Full Text] [Related]
29. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.
Montemurro F; Valabrega G; Aglietta M
Expert Opin Biol Ther; 2007 Feb; 7(2):257-68. PubMed ID: 17250463
[TBL] [Abstract][Full Text] [Related]
30. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.
Maris JM; Courtright J; Houghton PJ; Morton CL; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Jul; 51(1):42-8. PubMed ID: 18293383
[TBL] [Abstract][Full Text] [Related]
31. Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells.
Lui VW; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Tsang CM; Lei KI; Chan AT; Mok TS
Invest New Drugs; 2011 Dec; 29(6):1241-52. PubMed ID: 20571878
[TBL] [Abstract][Full Text] [Related]
32. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
Konecny GE; Venkatesan N; Yang G; Dering J; Ginther C; Finn R; Rahmeh M; Fejzo MS; Toft D; Jiang SW; Slamon DJ; Podratz KC
Br J Cancer; 2008 Mar; 98(6):1076-84. PubMed ID: 18334972
[TBL] [Abstract][Full Text] [Related]
33. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.
Lock R; Carol H; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Jun; 50(6):1181-9. PubMed ID: 18085673
[TBL] [Abstract][Full Text] [Related]
34. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
[TBL] [Abstract][Full Text] [Related]
35. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
[TBL] [Abstract][Full Text] [Related]
36. EGFR and HER2 inhibition in pancreatic cancer.
Walsh N; Kennedy S; Larkin A; Corkery B; O'Driscoll L; Clynes M; Crown J; O'Donovan N
Invest New Drugs; 2013 Jun; 31(3):558-66. PubMed ID: 23076814
[TBL] [Abstract][Full Text] [Related]
37. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.
Houghton PJ; Morton CL; Kolb EA; Gorlick R; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2008 Apr; 50(4):799-805. PubMed ID: 17635004
[TBL] [Abstract][Full Text] [Related]
38. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
39. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
40. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
